Nebilet Hct (Hydrochlorothiazide, Nebivolol)

Nebivolol / Hydrochlorothiazide, the active ingredient in Nebilet Hct, is a beta‑blocker and thiazide diuretic presented as an oral tablet for oral use. It is used to lower blood pressure in adults with essential hypertension.

GNH USA supplies Nebilet Hct as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebilet Hct combines nebivolol and hydrochlorothiazide to treat hypertension by targeting cardiovascular and renal mechanisms.

- Essential hypertension: lowers systolic and diastolic blood pressure in patients with primary high blood pressure. - Hypertension with fluid retention: reduces plasma volume while providing beta‑blockade to improve blood pressure control. - Hypertension requiring beta‑blockade: offers heart‑rate control together with diuretic action for comprehensive management.

Common Side Effects: - Dizziness or light‑headedness. - Headache. - Increased urinary frequency. - Fatigue. - Electrolyte disturbances such as mild hypokalemia. - Erectile dysfunction.

Serious or Rare Side Effects: - Severe hypotension leading to syncope. - Bronchospasm, especially in patients with asthma or COPD. - Significant electrolyte imbalances (severe hyponatremia or hypokalemia). - Acute kidney injury. - Pancreatitis. - Allergic reactions such as rash or angioedema.

Nebilet Hct should be used with clinical monitoring and patient education. - Blood pressure monitoring: check regularly to avoid excessive lowering. - Renal function assessment: evaluate creatinine and eGFR before and during therapy. - Electrolyte surveillance: monitor serum potassium and sodium levels. - Caution in asthma/COPD: β1‑selectivity reduces risk but bronchospasm can still occur. - Do not discontinue abruptly: taper to prevent rebound hypertension. - Store at room temperature: keep in the original container, protect from moisture and light.

Nebilet Hct may interact with several medicines; clinicians should review patient medication lists.

Major Interactions (Avoid): - Other antihypertensives (e.g., ACE inhibitors, ARBs) may cause additive hypotension. - Potassium‑sparing diuretics can lead to hyperkalemia. - Non‑steroidal anti‑inflammatory drugs (NSAIDs) may reduce diuretic efficacy. - Strong CYP2D6 inhibitors (e.g., paroxetine) increase nebivolol plasma levels. - Lithium: concurrent use can raise lithium concentrations.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: monitor renal function and potassium. - Additional beta‑blockers: risk of excessive bradycardia. - Antidiabetic agents: beta‑blockade may mask hypoglycaemia symptoms. - Digoxin: diuretic‑induced electrolyte shifts can alter digoxin levels. - Alcohol: may enhance dizziness and hypotensive effects.